MedPath

Delta-Fly Pharma's Phase I/II Trial of DFP-10917 and Venetoclax Shows Promise in AML

• Delta-Fly Pharma's Phase I/II study combines DFP-10917 with Venetoclax for AML patients previously treated with Venetoclax, showing encouraging initial safety and efficacy data. • The trial aims to establish a safer alternative to the standard Azacitidine and Venetoclax combination, potentially leading to FDA approval through collaboration. • Enrollment is progressing smoothly, with the first three patients demonstrating promising results, suggesting further development of the novel therapy. • A Phase III study of DFP-10917 in relapsed/refractory AML patients is planned, with data cut-off anticipated due to decreasing long-term survivors.

Delta-Fly Pharma Inc. has announced encouraging initial data from its Phase I/II study evaluating the combination of DFP-10917 and venetoclax in patients with acute myeloid leukemia (AML) who have previously been treated with venetoclax. The study is currently enrolling patients in its Phase I portion, with the first three patients showing promising safety and efficacy results.
The trial is designed to explore a potentially safer alternative to the existing standard combination chemotherapy of azacitidine and venetoclax, which can be challenging for AML patients. Delta-Fly Pharma is pursuing a combination of DFP-10917 with venetoclax with the goal of securing NDA approval from the FDA, possibly through a collaboration with a major global pharmaceutical company.

DFP-10917: A Novel Approach for AML Treatment

DFP-10917 represents an innovative approach to treating AML, particularly in patients who have relapsed or are refractory to existing treatments. The company is also planning a Phase III study of DFP-10917 in relapsed/refractory AML patients. However, the data cut-off is planned due to the decreasing number of long-term survivors.
Delta-Fly Pharma is committed to developing innovative therapies for cancer patients and is actively seeking collaborations to advance its pipeline. Further inquiries can be directed to Yasundo Yamasaki, Ph.D., Director of Business Development at Delta-Fly Pharma, Inc.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Adjunctive MDD Treatment

Intra-Cellular Therapies has submitted an sNDA to the FDA for Caplyta (lumateperone) as an adjunctive treatment for major depressive disorder (MDD).
The sNDA is supported by positive Phase 3 results, demonstrating significant antidepressant efficacy and a favorable safety profile for Caplyta.

FDA Reviewing RP1 and Nivolumab Combination for Advanced Melanoma After PD-1 Inhibitor Failure

The FDA is evaluating a biologics license application for RP1 plus nivolumab to treat advanced melanoma in adults who have previously received a PD-1 inhibitor.
The application is supported by data from the phase 1/2 IGNYTE trial, which demonstrated an overall response rate of 32.7% in patients with anti-PD-1-failed melanoma.

Delta-Fly Pharma Advances Solid Tumor and Pancreatic Cancer Programs

Delta-Fly Pharma's DFP-14927, a drug delivery formulation of DFP-10917, is undergoing an expanded Phase I study in R/R colorectal cancer patients at MD Anderson and UCLA.
DFP-17729, in combination with TS-1, receives PMDA approval for a Phase II/III clinical trial in pancreatic cancer patients after third-line treatment.

Delta-Fly Pharma's DFP-10917 Shows Promise in Combination with Venetoclax for AML

Delta-Fly Pharma's Phase I/II study of DFP-10917 with Venetoclax in AML patients previously treated with Venetoclax is underway, with patient enrollment progressing well.
Early results from the first three patients indicate encouraging safety and efficacy profiles for the DFP-10917 and Venetoclax combination therapy.

Delta-Fly Pharma's DFP-10917 Shows Promise in Combination with Venetoclax for AML

Delta-Fly Pharma's Phase I/II study of DFP-10917 with venetoclax in AML patients who have previously been treated with venetoclax is underway.
Early data from the first three patients in the Phase I portion show encouraging safety and efficacy results, suggesting further development.

Novocure's Optune Lua Receives FDA Approval for Metastatic Non-Small Cell Lung Cancer

The FDA has approved Novocure's Optune Lua for metastatic non-small cell lung cancer (mNSCLC) in adults who have progressed on or after platinum-based therapy.
The approval was based on the Phase 3 LUNAR trial, which showed a statistically significant 3.3-month extension in median overall survival with Optune Lua.

Delta-Fly Pharma Initiates Phase I/II Trial of DFP-10917 with Venetoclax for Relapsed/Refractory AML

Delta-Fly Pharma's Phase I/II trial of DFP-10917 combined with Venetoclax in relapsed/refractory AML patients has enrolled its first patient.
The trial, approved by the FDA, will evaluate the combination therapy's complete remission rate and progression-free survival in up to 39 patients.

FDA Approves Blinatumomab for Early-Stage CD19-Positive B-ALL

The FDA has approved blinatumomab for adult and pediatric patients with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase.
The approval was based on the Phase 3 E1910 trial, which showed a significant improvement in overall survival when blinatumomab was added to consolidation chemotherapy.

LYT-200 Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia Treatment

The FDA has granted orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for the treatment of acute myeloid leukemia (AML). LYT-200 is currently undergoing phase 1 trials for AML, solid tumors, and myelodysplastic syndrome (MDS), showing promising safety and tolerability profiles.

Alentis Therapeutics Reports Positive Topline Results from Phase 1 Multiple Ascending Dose Cohorts Study

Alentis Therapeutics announced positive results from the multiple-ascending dose part of its first-in-human Phase 1 clinical study of ALE.F02, targeting Claudin-1. The study confirmed ALE.F02's safety and tolerability across multiple dose levels, with no serious adverse events reported. The findings support the progression to further clinical trials in liver and renal studies.

Reference News

[1]
Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients ...
shorelinebeacon.com · Oct 28, 2024

Delta-Fly Pharma's Phase I/II study of DFP-10917 and Venetoclax in AML patients shows promising initial results, aiming ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy